← All indications
Thyroid Cancer, Papillary
An ADENOCARCINOMA that originates from follicular cells of the THYROID GLAND and accounts for the majority of THYROID CANCER cases. Cells exhibit enlarged, oval, or elongated morphologies with clear, round, nuclei. Fusions of RET, NTRK1, TPM3, and PCM1 genes are associated with this cancer.
Drugs by status
Phase 4 trials (2)
Phase 3 trials (3)
Phase 2 trials (19)
Phase 1 trials (7)
Other trials (3)
Organizations
Organization Involved with Phase 2 Indications (23)
- Eisai
- Roche
- Exelixis
- Pfizer
- Ignyta, Inc.
- National Cancer Institute (NCI)
- Academic and Community Cancer Research United
- Cornell University
- Emory University
- Georgetown University
- University of Washington
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Ohio State University
- University of South Florida
- Mayo Clinic
- University of Chicago
- Leiden University
- Loxo Oncology
- University of Texas at Houston
- University of North Carolina at Chapel Hill
- National Comprehensive Cancer Network
- Memorial Sloan-Kettering Cancer Center
- Vall d'Hebron Institute of Research, Galatea Clinic
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (6)